International Stem Cell Corporation – OTC:ISCO

International Stem Cell stock price today

$0.18
+0.07
+80%
Financial Health
0
1
2
3
4
5
6
7
8
9

International Stem Cell stock price monthly change

-11.82%
month

International Stem Cell stock price quarterly change

-11.82%
quarter

International Stem Cell stock price yearly change

+25.00%
year

International Stem Cell key metrics

Market Cap
1.60M
Enterprise value
1.80M
P/E
-5
EV/Sales
0.14
EV/EBITDA
9.31
Price/Sales
0.13
Price/Book
-0.35
PEG ratio
-0.07
EPS
-0.06
Revenue
7.83M
EBITDA
-27K
Income
-311K
Revenue Q/Q
2.06%
Revenue Y/Y
-5.02%
Profit margin
-2.8%
Oper. margin
-1.04%
Gross margin
61.46%
EBIT margin
-1.04%
EBITDA margin
-0.34%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

International Stem Cell stock price history

International Stem Cell stock forecast

International Stem Cell financial statements

International Stem Cell Corporation (OTC:ISCO): Profit margin
Jun 2023 1.84M 492K 26.72%
Sep 2023 1.97M -131K -6.64%
Dec 2023 1.88M -458K -24.25%
Mar 2024 2.12M -214K -10.05%
International Stem Cell Corporation (OTC:ISCO): Debt to assets
Jun 2023 5786000 9.63M 166.47%
Sep 2023 5641000 9.5M 168.41%
Dec 2023 5390000 5.27M 97.9%
Mar 2024 5369000 5.33M 99.33%
International Stem Cell Corporation (OTC:ISCO): Cash Flow
Jun 2023 490K -51K 0
Sep 2023 62K -14K 0
Dec 2023 161K -3K 0
Mar 2024 -193K -9K 0

International Stem Cell alternative data

International Stem Cell Corporation (OTC:ISCO): Employee count
Aug 2023 29
Sep 2023 29
Oct 2023 29
Nov 2023 29
Dec 2023 29
Jan 2024 29
Feb 2024 29
Mar 2024 29
Apr 2024 29
May 2024 29
Jun 2024 29
Jul 2024 29

International Stem Cell other data

0.00% 0.00%
of ISCO is owned by hedge funds
20 +0
shares is hold by hedge funds

International Stem Cell Corporation (OTC:ISCO): Insider trades (number of shares)
Period Buy Sel
Jun 2018 0 1400
Jul 2018 0 3933
Aug 2018 0 14204
Oct 2018 0 1494
Dec 2018 0 12436
Jan 2019 599222 0
Apr 2019 0 1350
Transaction Date Insider Security Shares Price per share Total value Source
Sale
MAIER PAUL V director
Common Stock 1,350 N/A N/A
Purchase
SEMECHKIN ANDREY director, 10 perc.. Common Stock 599,222 $1.75 $1,048,639
Sale
GARNETTE SOPHIA officer: VP, Lega.. Common Stock 10,636 $1.54 $16,379
Option
GARNETTE SOPHIA officer: VP, Lega.. Common Stock 7,858 $1.1 $8,644
Option
GARNETTE SOPHIA officer: VP, Lega.. Common Stock 2,778 $1.09 $3,028
Option
GARNETTE SOPHIA officer: VP, Lega.. Stock Option (Right to Buy) 2,778 $1.09 $3,028
Option
GARNETTE SOPHIA officer: VP, Lega.. Stock Option (Right to Buy) 7,858 $1.1 $8,644
Option
KERN RUSSELL director, 10 perc.. Common Stock 1,800 $1.09 $1,962
Sale
KERN RUSSELL director, 10 perc.. Common Stock 1,800 $1.09 $1,962
Option
KERN RUSSELL director, 10 perc.. Stock Option (Right to Buy) 1,800 $1.09 $1,962
  • What's the price of International Stem Cell stock today?

    One share of International Stem Cell stock can currently be purchased for approximately $0.18.

  • When is International Stem Cell's next earnings date?

    Unfortunately, International Stem Cell's (ISCO) next earnings date is currently unknown.

  • Does International Stem Cell pay dividends?

    No, International Stem Cell does not pay dividends.

  • How much money does International Stem Cell make?

    International Stem Cell has a market capitalization of 1.60M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 4.78% to 7.79M US dollars.

  • What is International Stem Cell's stock symbol?

    International Stem Cell Corporation is traded on the OTC under the ticker symbol "ISCO".

  • What is International Stem Cell's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of International Stem Cell?

    Shares of International Stem Cell can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are International Stem Cell's key executives?

    International Stem Cell's management team includes the following people:

    • Ms. Sophia Garnette J.D. Vice President of Legal Affairs & Operations, Principal Financial Officer and Sec.(age: 41, pay: $169,960)
    • Dr. Russell Kern Executive Vice President, Chief Scientific Officer & Director(age: 39, pay: $53,970)
    • Dr. Andrey Semechkin Co-Chairman & Chief Executive Officer(age: 65, pay: $53,970)
  • How many employees does International Stem Cell have?

    As Jul 2024, International Stem Cell employs 29 workers.

  • When International Stem Cell went public?

    International Stem Cell Corporation is publicly traded company for more then 18 years since IPO on 8 Jan 2007.

  • What is International Stem Cell's official website?

    The official website for International Stem Cell is internationalstemcell.com.

  • Where are International Stem Cell's headquarters?

    International Stem Cell is headquartered at 5950 Priestly Drive, Carlsbad, CA.

  • How can i contact International Stem Cell?

    International Stem Cell's mailing address is 5950 Priestly Drive, Carlsbad, CA and company can be reached via phone at +7 609406383.

International Stem Cell company profile:

International Stem Cell Corporation

internationalstemcell.com
Exchange:

OTC

Full time employees:

26

Industry:

Biotechnology

Sector:

Healthcare

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in North America, Asia, Europe, and internationally. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; and develops, manufactures, and markets anti-aging skincare and human cell culture products. The company's human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. The company sells skincare products through a website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

5950 Priestly Drive
Carlsbad, CA 92131

CIK: 0001355790
:
: